Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Nonsurgical treatment of recurrent glioblastoma.
Gallego O. Gallego O. Curr Oncol. 2015 Aug;22(4):e273-81. doi: 10.3747/co.22.2436. Curr Oncol. 2015. PMID: 26300678 Free PMC article. Review.
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C. Sepúlveda JM, et al. Among authors: gallego o. Clin Transl Oncol. 2015 Sep;17(9):743-50. doi: 10.1007/s12094-015-1304-0. Epub 2015 Jun 2. Clin Transl Oncol. 2015. PMID: 26033428 Clinical Trial.
O(6)-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 12 pts, unmethylated in 6 pts, and missing in 14 pts. ...
O(6)-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 12 pts, unmethylated in 6 pts, and missing in 14 pts. ...
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Balaña C, et al. Among authors: gallego o. Clin Transl Oncol. 2018 Dec;20(12):1529-1537. doi: 10.1007/s12094-018-1883-7. Epub 2018 May 8. Clin Transl Oncol. 2018. PMID: 29737461
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Among authors: gallego o. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Sepúlveda-Sánchez JM, et al. Among authors: gallego o. Neuro Oncol. 2017 Oct 19;19(11):1522-1531. doi: 10.1093/neuonc/nox105. Neuro Oncol. 2017. PMID: 28575464 Free PMC article. Clinical Trial.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: gallego o. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G, Martínez-Sales V, Vila V, Balañá C, Pérez-Segura P, Vaz MA, Benavides M, Gallego O, Palomero I, Gil-Gil M, Fleitas T, Reche E. Reynés G, et al. Among authors: gallego o. Anticancer Drugs. 2016 Feb;27(2):133-7. doi: 10.1097/CAD.0000000000000314. Anticancer Drugs. 2016. PMID: 26574999 Clinical Trial.
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.
Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A. Gallego O, et al. J Neurooncol. 2014 Jan;116(2):413-9. doi: 10.1007/s11060-013-1316-y. Epub 2013 Dec 19. J Neurooncol. 2014. PMID: 24352766 Free PMC article.
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G, Balañá C, Gallego O, Iglesias L, Pérez P, García JL. Reynés G, et al. Among authors: gallego o. Anticancer Drugs. 2014 Jul;25(6):717-22. doi: 10.1097/CAD.0000000000000059. Anticancer Drugs. 2014. PMID: 24322542 Clinical Trial.
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, Herrero A, Andrés R, Benavides M, Quintanar T, Pérez-Martin X. Gil MJ, et al. Among authors: gallego o. Anticancer Drugs. 2012 Jul;23(6):659-65. doi: 10.1097/CAD.0b013e3283534d3e. Anticancer Drugs. 2012. PMID: 22634799
79 results
Jump to page
Feedback